These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30808564)

  • 1. Central precocious puberty in girls: Diagnostic study and auxological response to triptorelin treatment.
    Durá-Travé T; Ortega Pérez M; Ahmed-Mohamed L; Moreno-González P; Chueca Guindulain MJ; Berrade-Zubiri S
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):410-416. PubMed ID: 30808564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
    Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Lasorella S; Porto R; Iezzi ML; Pistone C; Marseglia GL; Verrotti A; Brambilla I
    Gynecol Endocrinol; 2020 Apr; 36(4):338-340. PubMed ID: 31441342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopregnanolone levels decrease after gonadotropin-releasing hormone analog stimulation test in girls with central precocious puberty.
    Predieri B; Luisi S; Casarosa E; Farinelli E; Antoniazzi F; Wasniewska M; Bernasconi S; Petraglia F; Iughetti L;
    J Endocrinol Invest; 2011 Jan; 34(1):38-44. PubMed ID: 20530984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy.
    Vukovic R; Milenkovic T; Soldatovic I; Pekic S; Mitrovic K; Todorovic S
    Endocrine; 2022 Mar; 75(3):934-941. PubMed ID: 34826116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Triptorelin therapy in girls with central precocious puberty increases body mass index].
    Martín Díaz MJ; Soriano Guillén L; Muñoz Calvo MT; Pozo Román J; Argente Oliver J
    An Pediatr (Barc); 2006 Nov; 65(5):428-33. PubMed ID: 17184602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
    Léger J; Reynaud R; Czernichow P
    J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty.
    Freire AV; Gryngarten MG; Ballerini MG; Arcari AJ; Escobar ME; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2016; 85(1):58-64. PubMed ID: 26675317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.